Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Gains from Investment Securities (2016 - 2025)

Iradimed (IRMD) has disclosed Gains from Investment Securities for 13 consecutive years, with $29559.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 99.34% to $29559.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 52.54% decrease, with the full-year FY2024 number at $134816.0, down 4.61% from a year prior.
  • Gains from Investment Securities was $29559.0 for Q3 2025 at Iradimed, down from $95994.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.5 million in Q3 2024 to a low of -$755396.0 in Q4 2022.
  • A 5-year average of $419188.6 and a median of $95994.0 in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 495.52% in 2021, then soared 1824.08% in 2024.
  • Iradimed's Gains from Investment Securities stood at $535470.0 in 2021, then plummeted by 241.07% to -$755396.0 in 2022, then soared by 150.62% to $382365.0 in 2023, then skyrocketed by 437.44% to $2.1 million in 2024, then tumbled by 98.56% to $29559.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Gains from Investment Securities are $29559.0 (Q3 2025), $95994.0 (Q2 2025), and $116297.0 (Q1 2025).